Previous close | 8.71 |
Open | 8.77 |
Bid | 9.00 x 1000 |
Ask | 9.02 x 800 |
Day's range | 8.27 - 8.77 |
52-week range | 1.33 - 11.11 |
Volume | |
Avg. volume | 440,338 |
Market cap | 392.617M |
Beta (5Y monthly) | 2.13 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.05 |
Earnings date | 07 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 15.50 |
Shattuck Labs ( NASDAQ:STTK ) Full Year 2023 Results Key Financial Results Net loss: US$87.3m (loss narrowed by 14...
AUSTIN, TX and DURHAM, NC, March 04, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced the appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors, effective March 1, 2024. Both Dr. Siegall and Dr. Sasser are highly successful execu
- Announced positive topline data from the ongoing Phase 1A/B clinical trial of SL-172154 in combination with azacitidine (AZA) in frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and frontline TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) patients; initial data build on the dose-escalation data featured in a poster presentation at the American Society of Hematology (ASH) Annual Meeting – - Completed initial enrollment in Phase 1B dose-expansion cohorts for frontline HR-MDS and TP53m